Vir Biotechnology (VIR) Payables (2018 - 2026)

Vir Biotechnology has disclosed Payables across 9 years of filings, most recently posting $5.4 million for Q1 2026.

• Payables for Q1 2026 came in at $5.4 million, up 46.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 46.17% YoY), and the FY2025 annual result was $9.8 million, up 92.93% from the prior year.
• Payables came in at $5.4 million for Q1 2026 at Vir Biotechnology, down from $9.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $12.4 million in Q2 2023 to a low of $2.7 million in Q3 2022.
• The 5-year median for Payables is $6.8 million (2025), against an average of $7.5 million.
• Across the five-year window, Payables soared 196.0% in 2022 and sank 64.5% in 2024, its largest moves.
• Vir Biotechnology's Payables stood at $6.4 million in 2022, then slipped by 1.37% to $6.3 million in 2023, then retreated by 19.78% to $5.1 million in 2024, then soared by 92.93% to $9.8 million in 2025, then sank by 44.46% to $5.4 million in 2026.
• The last three Payables figures came in at $5.4 million (Q1 2026), $9.8 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.